DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Patent: RE39155

Summary for Patent: RE39155

Title:Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B
Abstract:Use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment of hepatitis B is disclosed. ##STR00001##
Inventor(s): Belleau; Pierrette (Montreal, CA), Nguyen-Ba; Nghe (La Praire, CA), Belleau; Bernard (Westmont, CA)
Assignee: Shire BioChem Inc. (Quebec, CA)
Application Number:09/585,431
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent PDF download available with subscription

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxosmithkline
EPIVIR-HBV
lamivudine
SOLUTION;ORAL021004Dec 8, 1998RXYesRE39155*PED<disabled>
Glaxosmithkline
EPIVIR-HBV
lamivudine
TABLET;ORAL021003Dec 8, 1998RXYesRE39155*PED<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: RE39155

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9100039Jan 03, 1991
United Kingdom9109913May 07, 1991
PCT Information
PCT FiledJanuary 03, 1992PCT Application Number:PCT/CA92/00001
PCT Publication Date:July 23, 1992PCT Publication Number: WO92/11852

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc